Syndax Pharmaceuticals prices $150M public offering of 6.8M shares at $22.00 per share

Syndax Pharmaceuticals Inc

6,818,182 shares offered at $22.00 each; underwriters have 30-day option for 1,022,727 additional shares.
Gross proceeds expected ~$150M ($172.5M if option fully exercised).
Underwriting led by Goldman Sachs, J.P. Morgan, and Cowen; closing expected December 9, 2022.
Directors, executive officers, and company subject to 60-day lock-up on share sales without consent.
Offering made under effective shelf registration statement (File No. 333-254661).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Syndax Pharmaceuticals Inc entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC valued at approximately $150.0 million (effective 2022-12-06).

Action: entry
Agreement: underwriting
Counterparty: Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC
Value: approximately $150.0 million
Effective: 2022-12-06

Exact text from the filing

On December 6, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the “ Underwriters ”), relating to the issuance and sale of 6,818,182 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $22.00 per share (the “ Offering ”).

View on SEC.gov

Browse all material agreements →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001193125-22-300218

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.